JADE2

Summary

JADE2 (jade family PHD finger 2, HGNC:22984) is a protein-coding gene on chromosome 5q31.1, encoding E3 ubiquitin-protein ligase Jade-2 (Q9NQC1). Scaffold subunit of some HBO1 complexes, which have a histone H4 acetyltransferase activity.

Enables histone H4K12 acetyltransferase activity; histone H4K5 acetyltransferase activity; and histone H4K8 acetyltransferase activity. Contributes to histone H3K14 acetyltransferase activity. Involved in regulation of DNA biosynthetic process; regulation of DNA replication; and regulation of cell cycle. Located in nucleoplasm. Part of histone acetyltransferase complex.

Source: NCBI Gene 23338 — RefSeq curated summary.

At a glance

• GWAS associations: 45
• Clinical variants (ClinVar): 102 total
• MANE Select transcript: NM_001388185

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22984
Approved symbol	JADE2
Name	jade family PHD finger 2
Location	5q31.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0239, JADE-2
Ensembl gene	ENSG00000043143
Ensembl biotype	protein_coding
OMIM	610515
Entrez	23338

Gene structure

Transcript identifiers

Ensembl transcripts: 42 — 35 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000282605, ENST00000361895, ENST00000395003, ENST00000402835, ENST00000430087, ENST00000431355, ENST00000453515, ENST00000470876, ENST00000512386, ENST00000515554, ENST00000612830, ENST00000680418, ENST00000681019, ENST00000681498, ENST00000681547, ENST00000681792, ENST00000681820, ENST00000892462, ENST00000892463, ENST00000892464, ENST00000892465, ENST00000892466, ENST00000892467, ENST00000892468, ENST00000892470, ENST00000892471, ENST00000892474, ENST00000892476, ENST00000892478, ENST00000892479, ENST00000892481, ENST00000930756, ENST00000930757, ENST00000930758, ENST00000930759, ENST00000930760, ENST00000930761, ENST00000930762, ENST00000946716, ENST00000946717, ENST00000946718, ENST00000946719

RefSeq mRNA: 8 — MANE Select: NM_001388185 NM_001289984, NM_001289985, NM_001308143, NM_001388185, NM_001388186, NM_001388187, NM_001388188, NM_015288

CCDS: CCDS4176, CCDS75305, CCDS78061, CCDS93782

Canonical transcript exons

ENST00000681547 — 12 exons

Exon	Start	End
ENSE00001006706	134537989	134538083
ENSE00001274664	134573645	134573762
ENSE00001274680	134562200	134562367
ENSE00001274730	134564494	134564610
ENSE00001274738	134560746	134560957
ENSE00003465802	134552052	134552209
ENSE00003520701	134535858	134535915
ENSE00003540202	134576768	134576896
ENSE00003603447	134566116	134566580
ENSE00003644936	134559830	134559990
ENSE00003915168	134525670	134526011
ENSE00003922142	134578494	134583227

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 94.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.5110 / max 145.1104, expressed in 1751 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58584	8.1864	1583
58582	1.7747	883
58583	1.3192	738
58586	0.7732	423
58587	0.7092	384
58585	0.6878	360
58590	0.0274	12
58588	0.0201	11
58589	0.0130	7

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	94.01	gold quality
middle temporal gyrus	UBERON:0002771	93.75	gold quality
endothelial cell	CL:0000115	93.06	gold quality
granulocyte	CL:0000094	92.32	gold quality
Brodmann (1909) area 10	UBERON:0013541	91.72	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.59	gold quality
eye	UBERON:0000970	91.47	gold quality
sural nerve	UBERON:0015488	91.11	gold quality
CA1 field of hippocampus	UBERON:0003881	90.84	gold quality
parotid gland	UBERON:0001831	90.56	gold quality
lymph node	UBERON:0000029	90.29	gold quality
metanephric glomerulus	UBERON:0004736	89.82	gold quality
renal glomerulus	UBERON:0000074	89.80	gold quality
blood	UBERON:0000178	89.52	gold quality
superficial temporal artery	UBERON:0001614	89.33	gold quality
right adrenal gland cortex	UBERON:0035827	89.15	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.96	gold quality
visceral pleura	UBERON:0002401	88.93	gold quality
postcentral gyrus	UBERON:0002581	88.93	gold quality
right adrenal gland	UBERON:0001233	88.87	gold quality
primary visual cortex	UBERON:0002436	88.70	gold quality
seminal vesicle	UBERON:0000998	88.65	gold quality
left adrenal gland cortex	UBERON:0035825	88.54	gold quality
entorhinal cortex	UBERON:0002728	88.49	gold quality
adrenal cortex	UBERON:0001235	88.48	gold quality
lateral nuclear group of thalamus	UBERON:0002736	88.43	gold quality
parietal lobe	UBERON:0001872	88.39	gold quality
superior frontal gyrus	UBERON:0002661	88.15	gold quality
adult organism	UBERON:0007023	88.03	gold quality
left adrenal gland	UBERON:0001234	87.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

198 targeting JADE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-185-3P	99.95	67.01	1743

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	jade2	ENSDARG00000053389
mus_musculus	Jade2	ENSMUSG00000020387
rattus_norvegicus	Jade2	ENSRNOG00000004956
drosophila_melanogaster	Br140	FBGN0033155
caenorhabditis_elegans		WBGENE00003034
caenorhabditis_elegans		WBGENE00021810

Paralogs (8): JADE1 (ENSG00000077684), MLLT10 (ENSG00000078403), BRPF3 (ENSG00000096070), BRD1 (ENSG00000100425), JADE3 (ENSG00000102221), PHF14 (ENSG00000106443), BRPF1 (ENSG00000156983), MLLT6 (ENSG00000275023)

Protein

Protein identifiers

E3 ubiquitin-protein ligase Jade-2 — Q9NQC1 (reviewed: Q9NQC1)

Alternative names: Jade family PHD finger protein 2, PHD finger protein 15

All UniProt accessions (10): A0A087X085, A0A0C4DFT8, A0A7P0T8T0, A0A7P0TAP8, A0A7P0Z4H4, B5MBX1, C9J929, Q9NQC1, G3XAA4, H7C0P2

UniProt curated annotations — full annotation on UniProt →

Function. Scaffold subunit of some HBO1 complexes, which have a histone H4 acetyltransferase activity. Acts as an E3 ubiquitin-protein ligase mediating the ubiquitination and subsequent proteasomal degradation of target protein histone demethylase KDM1A. Also acts as a ubiquitin ligase E3 toward itself. Positive regulator of neurogenesis.

Subunit / interactions. Component of the HBO1 complex composed at least of ING4 or ING5, MYST2/HBO1, MEAF6, and one of JADE1, JADE2 and JADE3. Interacts (via C-terminus) with KDM1A (via AOD/Tower domain).

Domain organisation. The first PHD domain is essential for its E3 ubiquitin ligase activity.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the JADE family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NQC1-1	1	yes
Q9NQC1-2	2
Q9NQC1-3	3

RefSeq proteins (8): NP_001276913, NP_001276914, NP_001295072, NP_001375114, NP_001375115, NP_001375116, NP_001375117, NP_056103 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001965	Znf_PHD	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR019542	Enhancer_polycomb-like_N	Domain
IPR019786	Zinc_finger_PHD-type_CS	Conserved_site
IPR019787	Znf_PHD-finger	Domain
IPR034732	EPHD	Domain
IPR039548	JADE2_PHD	Domain
IPR039549	JADE2_ePHD	Domain
IPR050701	Histone_Mod_Regulator	Family

Pfam: PF10513, PF13831, PF13832

UniProt features (26 total): compositionally biased region 6, modified residue 6, region of interest 4, zinc finger region 3, splice variant 2, mutagenesis site 2, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQC1-F1	62.79	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 9, 15, 32, 38, 117, 298

Mutagenesis-validated functional residues (2):

Position	Phenotype
202	loss of e3 ubiquitin-protein ligase activity on kdm1a.
243	loss of e3 ubiquitin-protein ligase activity on kdm1a.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization

MSigDB gene sets: 404 (showing top): E2F_Q4, E2F_Q4_01, RRAGTTGT_UNKNOWN, FREAC2_01, PAX4_01, TGCGCANK_UNKNOWN, E2F4DP1_01, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, AAGTCCA_MIR422B_MIR422A, CMYB_01, TTTGTAG_MIR520D, SP3_Q3, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOBP_GROWTH, MODULE_493

GO Biological Process (13): regulation of cell growth (GO:0001558), regulation of DNA replication (GO:0006275), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), protein ubiquitination (GO:0016567), regulation of cell cycle (GO:0051726), regulation of DNA biosynthetic process (GO:2000278), protein polyubiquitination (GO:0000209), chromatin remodeling (GO:0006338), regulation of neurogenesis (GO:0050767), positive regulation of neurogenesis (GO:0050769), protein autoubiquitination (GO:0051865), neuron projection extension (GO:1990138)

GO Molecular Function (9): zinc ion binding (GO:0008270), histone H4K5 acetyltransferase activity (GO:0043995), histone H4K8 acetyltransferase activity (GO:0043996), histone H4K12 acetyltransferase activity (GO:0043997), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), histone H3K14 acetyltransferase activity (GO:0036408), metal ion binding (GO:0046872)

GO Cellular Component (3): histone acetyltransferase complex (GO:0000123), nucleoplasm (GO:0005654), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Chromatin organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
histone H4 acetyltransferase activity	3
regulation of DNA metabolic process	2
protein ubiquitination	2
neurogenesis	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
DNA replication	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
protein modification by small protein conjugation	1
cell cycle	1
regulation of cellular process	1
regulation of macromolecule biosynthetic process	1
DNA biosynthetic process	1
chromatin organization	1
regulation of nervous system development	1
regulation of cell development	1
positive regulation of cell development	1
regulation of neurogenesis	1
positive regulation of nervous system development	1
developmental cell growth	1
neuron projection morphogenesis	1
developmental growth involved in morphogenesis	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
histone H3 acetyltransferase activity	1
cation binding	1
chromatin	1
protein acetyltransferase complex	1
nuclear lumen	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

530 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
JADE2	SETD1A	O15047	719
JADE2	KAT7	O95251	696
JADE2	MEAF6	Q9HAF1	671
JADE2	ING4	Q9UNL4	641
JADE2	CCDC198	Q9NVL8	480
JADE2	JADE3	Q92613	470
JADE2	PROB1	E7EW31	469
JADE2	JADE1	Q6IE81	468
JADE2	OR10G6	Q8NH81	454
JADE2	USP28	Q96RU2	449
JADE2	ING5	Q8WYH8	438
JADE2	BRPF3	Q9ULD4	428
JADE2	ING3	Q9NXR8	427
JADE2	CEBPG	P53567	385
JADE2	WNT3A	P56704	383

IntAct

24 interactions, top by confidence:

A	B	Type	Score
JADE2	ING5	psi-mi:“MI:0915”(physical association)	0.740
ING5	JADE2	psi-mi:“MI:0915”(physical association)	0.740
JADE2	ING4	psi-mi:“MI:0915”(physical association)	0.660
ING4	KAT7	psi-mi:“MI:0914”(association)	0.530
ING5	KAT7	psi-mi:“MI:0914”(association)	0.530
ZBTB5	JADE2	psi-mi:“MI:0915”(physical association)	0.370
JADE2	ZBTB3	psi-mi:“MI:0915”(physical association)	0.370
JADE2	ZNF496	psi-mi:“MI:0915”(physical association)	0.370
JADE2	MYO9A	psi-mi:“MI:0914”(association)	0.350
MEAF6	KPNA5	psi-mi:“MI:0914”(association)	0.350
ING5	CCDC85C	psi-mi:“MI:0914”(association)	0.350
JADE2	KAT7	psi-mi:“MI:0914”(association)	0.350
PACSIN1	JADE2	psi-mi:“MI:0915”(physical association)	0.000
JADE2		psi-mi:“MI:0915”(physical association)	0.000
JADE2	pcm	psi-mi:“MI:0915”(physical association)	0.000
JADE2	gpmI	psi-mi:“MI:0915”(physical association)	0.000
aer	JADE2	psi-mi:“MI:0915”(physical association)	0.000
JADE2	pog	psi-mi:“MI:0915”(physical association)	0.000
TTC3	JADE2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (103): GORASP2 (Two-hybrid), ING5 (Two-hybrid), MYO9A (Affinity Capture-MS), MEAF6 (Affinity Capture-MS), ING4 (Affinity Capture-MS), ING5 (Affinity Capture-MS), MYO5C (Affinity Capture-MS), ING3 (Affinity Capture-MS), PIK3R4 (Affinity Capture-MS), PIK3C3 (Affinity Capture-MS), CCDC88A (Affinity Capture-MS), CCDC93 (Affinity Capture-MS), KAT7 (Affinity Capture-MS), CCP110 (Affinity Capture-MS), C14orf80 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8F1M4, A0A8M9QN10, A0JMQ9, A6NIR3, A8DZE6, A8WH69, B2KF05, F1QCY8, O43147, O43900, O54880, P0C6P5, P59729, P97433, Q13009, Q18PD9, Q2NKQ1, Q32L09, Q3U5C7, Q58D79, Q5EB20, Q5PQS0, Q5U464, Q60592, Q6IVY4, Q6P0Q8, Q6ZQF7, Q6ZUJ8, Q71QF9, Q768S4, Q7T2V3, Q7TNN8, Q7TSI1, Q7ZVP1, Q803A0, Q80U12, Q80VL3, Q80Y24, Q8BPQ7, Q8BRB7

Diamond homologs: A0A286Y9D1, A1YVX4, A7E320, B2KF05, B2RRD7, B6CHA3, F4KBP5, F6UA42, G5E8P1, G5EBZ4, O54826, O75164, O94880, O94953, P0CB22, P29375, P34447, P41229, P41230, P47156, P55197, P55198, P55201, Q0P4S5, Q12311, Q20318, Q22516, Q29EQ3, Q30DN6, Q38JA7, Q3UXZ9, Q5E9T7, Q5RD88, Q5TKR9, Q62240, Q6GQJ2, Q6IE81, Q6IE82, Q6IQX0, Q6K431

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	95
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1768 predictions. Top by Δscore:

Variant	Effect	Δscore
5:134535916:G:GG	donor_gain	1.0000
5:134537984:T:TA	acceptor_gain	1.0000
5:134537985:GCAG:G	acceptor_loss	1.0000
5:134537986:CAGGT:C	acceptor_loss	1.0000
5:134537987:A:AG	acceptor_gain	1.0000
5:134537987:AG:A	acceptor_gain	1.0000
5:134537988:G:GT	acceptor_gain	1.0000
5:134537988:GG:G	acceptor_gain	1.0000
5:134537988:GGT:G	acceptor_gain	1.0000
5:134537988:GGTC:G	acceptor_gain	1.0000
5:134537988:GGTCA:G	acceptor_gain	1.0000
5:134538081:GAG:G	donor_gain	1.0000
5:134538081:GAGG:G	donor_loss	1.0000
5:134538084:G:GG	donor_gain	1.0000
5:134538084:G:T	donor_loss	1.0000
5:134552048:ACAG:A	acceptor_gain	1.0000
5:134552049:CA:C	acceptor_loss	1.0000
5:134552050:A:AG	acceptor_gain	1.0000
5:134552050:A:AT	acceptor_loss	1.0000
5:134552050:AG:A	acceptor_gain	1.0000
5:134552051:G:GT	acceptor_gain	1.0000
5:134552051:GG:G	acceptor_gain	1.0000
5:134552051:GGT:G	acceptor_gain	1.0000
5:134552051:GGTT:G	acceptor_gain	1.0000
5:134552051:GGTTT:G	acceptor_gain	1.0000
5:134559825:TCTA:T	acceptor_loss	1.0000
5:134559827:TA:T	acceptor_loss	1.0000
5:134559828:A:AG	acceptor_gain	1.0000
5:134559828:AG:A	acceptor_gain	1.0000
5:134559829:G:GG	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000021923 (5:134540696 T>A), RS1000100822 (5:134547117 A>G), RS1000102115 (5:134546716 C>T), RS1000154283 (5:134546951 T>C), RS1000179412 (5:134553454 T>C), RS1000182838 (5:134563298 A>G), RS1000224705 (5:134566752 A>G), RS1000299301 (5:134575357 G>C), RS1000347068 (5:134560081 A>G), RS1000433416 (5:134582348 G>A), RS1000449695 (5:134540830 G>A,C), RS1000558168 (5:134535880 A>C), RS1000696632 (5:134552968 G>A), RS1000844088 (5:134548365 C>A), RS1000909694 (5:134551969 T>A,C)

Disease associations

OMIM: gene MIM:610515 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

45 associations (top):

Study	Trait	p-value
GCST000880_41	Menarche (age at onset)	2.000000e-10
GCST002541_15	Menarche (age at onset)	3.000000e-20
GCST003795_5	Age at first birth	4.000000e-08
GCST003993_11	Menarche (age at onset)	4.000000e-08
GCST004616_11	Platelet distribution width	6.000000e-22
GCST004894_130	Type 2 diabetes	3.000000e-09
GCST004894_55	Type 2 diabetes	6.000000e-06
GCST004904_29	Body mass index	6.000000e-08
GCST004904_54	Body mass index	4.000000e-08
GCST005830_29	Hand grip strength	2.000000e-08
GCST006045_7	Age at first birth	1.000000e-07
GCST008103_44	Bipolar disorder	2.000000e-07
GCST008362_222	Birth weight	8.000000e-11
GCST008363_43	Offspring birth weight	3.000000e-17
GCST008526_29	Coffee consumption	3.000000e-06
GCST008550_2	Mental health study participation (completed survey)	9.000000e-09
GCST008550_22	Mental health study participation (completed survey)	4.000000e-09
GCST008550_3	Mental health study participation (completed survey)	2.000000e-08
GCST008550_4	Mental health study participation (completed survey)	8.000000e-09
GCST009379_44	Type 2 diabetes	4.000000e-09
GCST009524_268	Household income (MTAG)	7.000000e-11
GCST009597_121	Multiple sclerosis	2.000000e-13
GCST010118_47	Type 2 diabetes	2.000000e-08
GCST010702_165	Subcortical volume (MOSTest)	7.000000e-19
GCST010703_215	Brain morphology (MOSTest)	3.000000e-11
GCST010796_3576	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_3577	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-09
GCST010796_3578	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_3579	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_3617	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08

EFO canonical traits (16, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0009101	age at first birth measurement
EFO:0007984	platelet component distribution width
EFO:0004340	body mass index
EFO:0006941	grip strength measurement
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0006781	coffee consumption measurement
EFO:0010130	health study participation
EFO:0009695	household income
EFO:0004346	neuroimaging measurement
EFO:0004327	electrocardiography
EFO:0004319	smoking cessation
EFO:0005091	monocyte count
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	4
Valproic Acid	affects expression, decreases expression, increases expression	4
trichostatin A	affects expression, decreases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
entinostat	increases expression, affects cotreatment	2
monomethylarsonous acid	decreases expression, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
FR900359	decreases phosphorylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
bisphenol A	increases methylation	1
tris(2-butoxyethyl) phosphate	affects expression	1
methylparaben	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
aflatoxin B2	decreases methylation	1
coumarin	affects phosphorylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	decreases expression	1
3-deazaneplanocin	increases expression	1
di-n-butylphosphoric acid	affects expression	1
scriptaid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aldehydes	decreases expression	1
Arsenic	increases expression, affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.